Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.: MRD after immunochemotherapy in mantle-cell lymphoma

MLA

Pott, Christiane, et al. Molecular Remission Is an Independent Predictor of Clinical Outcome in Patients with Mantle Cell Lymphoma after Combined Immunochemotherapy: A European MCL Intergroup Study.: MRD after Immunochemotherapy in Mantle-Cell Lymphoma. Apr. 2010. EBSCOhost, https://doi.org/10.1182/blood-2009-06-230250⟩.

APA

Pott, C., Hoster, E., Delfau-Larue, M.-H., Beldjord, K., Böttcher, S., Asnafi, V., Plonquet, A., Siebert, R., Callet-Bauchu, E., Andersen, N., van Dongen, J., Klapper, W., Berger, F., Ribrag, V., van Hoof, A., Trneny, M., Walewski, J., Dreger, P., Unterhalt, M., … Dreyling, M. (2010). Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.: MRD after immunochemotherapy in mantle-cell lymphoma. https://doi.org/10.1182/blood-2009-06-230250⟩

Chicago

Pott, Christiane, Eva Hoster, Marie-Hélène Delfau-Larue, Kheira Beldjord, Sebastian Böttcher, Vahid Asnafi, Anne Plonquet, et al. 2010. “Molecular Remission Is an Independent Predictor of Clinical Outcome in Patients with Mantle Cell Lymphoma after Combined Immunochemotherapy: A European MCL Intergroup Study.: MRD after Immunochemotherapy in Mantle-Cell Lymphoma,” April. doi:10.1182/blood-2009-06-230250⟩.